Ovarian Cancer pp 319-334 | Cite as

Microenvironmental Regulation of Ovarian Cancer Metastasis

  • Maria V. Barbolina
  • Natalie M. Moss
  • Suzanne D. Westfall
  • Yueying Liu
  • Rebecca J. Burkhalter
  • Francoise Marga
  • Gabor Forgacs
  • Laurie G. Hudson
  • M. Sharon Stack
Part of the Cancer Treatment and Research book series (CTAR, volume 149)

Introduction: Ovarian Carcinoma Metastasis

Tumors arising from the ovarian surface epithelium (OSE) account for the vast majority of ovarian malignancies; however, the etiology of epithelial ovarian cancer (EOC) remains poorly understood,1 and the analysis of early events in ovarian carcinogenesis is limited by the relative lack of early-stage tumors for study. The normal OSE is a single layer of mesodermally derived cells that exhibit the remarkable ability to transition between epithelial and fibroblastic phenotypes in response to microenvironmental cues.2, 3, 4Such phenotypic plasticity is usually limited to immature, regenerating, or neoplastic epithelium. Unlike most carcinomas that initially de-differentiate during neoplastic progression, ovarian carcinomas undergo a mesenchymal-epithelial transition and acquire a more differentiated epithelial phenotype resulting in significant morphologic heterogeneity as tumors acquire increasingly complex differentiation reminiscent of the...


Epithelial Ovarian Cancer Ovarian Cancer Cell Connective Tissue Growth Factor Mesothelial Cell Ovarian Surface Epithelium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



- epidermal growth factor;


- heparin binding EGF;


- colony stimulating factor-1;


- 4′ 6-diamidino-2-phenylindole;


- protein kinase B;


- phosphoinositide-3-kinase;


–vascular endothelial growth factor;


multi-cellular aggregate;


epithelial ovarian cancer;


ovarian surface epithelium;


lysophosphatidic acid;


tumor necrosis factor;


matrix metalloproteinase



This work was supported by grants from the 2005–2006 and 2007–2008 Penny Severns Breast, Cervical and Ovarian Cancer Fund, Illinois Department of Public Health (M.V.B.), the Ovarian Cancer Research Foundation Program of Excellence (M.V.B.), National Science Foundation NSF-0526854 (G.F.), and National Institutes of Health/National Cancer Institute Research Grants RO1CA86984 (M.S.S.), RO1CA086984-S1 (N.M.), and RO1CA109545 (M.S.S. and L.G.H.).


  1. 1.
    Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26:995–1005.CrossRefPubMedGoogle Scholar
  2. 2.
    Wong AST, Auersperg N. Normal ovarian surface epithelium. Cancer Treat Res. 2002;107:161–183.PubMedGoogle Scholar
  3. 3.
    Darai E, Scoazec JY, Walker-Combrouze F, et al. Expression of cadherins in benign, borderline and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol. 1997;28:922–928.CrossRefPubMedGoogle Scholar
  4. 4.
    Alper O, DeSantis ML, Stromberg K, et al. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer. 2000;88:566–574.CrossRefPubMedGoogle Scholar
  5. 5.
    Auersperg N, Maines-Bandiera S, Dyck HG, et al. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest. 1994;71:510–518.PubMedGoogle Scholar
  6. 6.
    Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med. 2007;9:1–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Shih EM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518.PubMedGoogle Scholar
  8. 8.
    ACS Cancer Facts & Figures. Available at:
  9. 9.
    Hoskins WJ. Prospective on ovarian cancer; why prevent? J Cell Biochem Suppl. 1995;23:189–199.CrossRefPubMedGoogle Scholar
  10. 10.
    Ghosh S, Wu Y, Stack MS. Ovarian cancer-associated proteinases. Cancer Treat Res. 2002;107:331–354.PubMedGoogle Scholar
  11. 11.
    Burleson KM, Hansen LK, Skubitz APN. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 2004;21:685–697.CrossRefPubMedGoogle Scholar
  12. 12.
    Burleson KM, Casey RC, Skubitz KM, et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 2004;93:170–181.CrossRefPubMedGoogle Scholar
  13. 13.
    Burleson KM, Boente MP, Pambuccian SE, et al. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 2006;4:1–16.CrossRefGoogle Scholar
  14. 14.
    Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis. 2008;25:L643–L655.CrossRefGoogle Scholar
  15. 15.
    Kenny HA, Krausz T, Yamada SD, et al. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007;121:1463–1472.CrossRefPubMedGoogle Scholar
  16. 16.
    Offner FA, Obrist P, Stadlmann S, et al. IL6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine. 1995;7:542–547.CrossRefPubMedGoogle Scholar
  17. 17.
    Mustea A, Pirvulescu C, Konsgen D, et al. Decreased IL1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine. 2008;42:77–84.CrossRefPubMedGoogle Scholar
  18. 18.
    Freedman RS, Deavers M, Liu J, et al. Peritoneal inflammation – a microenvironment for epithelial ovarian cancer. J Transl Med. 2004;2:23–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Papadaki L, Beilby JOW. The fine structure of the surface epithelium of the human ovary. J Cell Sci. 1971;8:445–465.PubMedGoogle Scholar
  20. 20.
    Czernobilsky B, Moll R, Levy M, et al. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol. 1985;37:175–190.PubMedGoogle Scholar
  21. 21.
    Kruk PA, Uitto VJ, Firth JD, et al. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp Cell Res. 1994;215:97–108.CrossRefPubMedGoogle Scholar
  22. 22.
    Carreiras F, Denoux Y, Staedel C, et al. Expression and localization of alphav integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol. 1996;62:260–267.CrossRefPubMedGoogle Scholar
  23. 23.
    Skubitz AP, Bast RC, Wayner EA, et al. Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol. 1996;148:1445–1461.PubMedGoogle Scholar
  24. 24.
    Bridges JE, Englefield P, Boyd IE, et al. Expression of integrin adhesion molecules in normal ovary and epithelial ovarian tumors. Int J Gynecol Cancer. 1995;5:187–192.CrossRefPubMedGoogle Scholar
  25. 25.
    Shield K, Riley C, Quinn MA, et al. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007;14:6–11.Google Scholar
  26. 26.
    Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha5 integrin, which is a therapeutic target. Cancer Res. 2008;68:2329–2339.CrossRefPubMedGoogle Scholar
  27. 27.
    Moser TL, Pizzo SV, Bafetti LM, et al. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer. 1996;67:695–701.CrossRefPubMedGoogle Scholar
  28. 28.
    Fishman DA, Kearns AM, Chilikuri K, et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by α2β1 integrin–mediated interaction with type I collagen. Invasion Metastasis. 1998;18:15–26.CrossRefPubMedGoogle Scholar
  29. 29.
    Ellerbroek SM, Fishman DA, Kearns AS, et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 1999;59:1635–1641.PubMedGoogle Scholar
  30. 30.
    Barbolina MV, Adley BP, Ariztia EV, et al. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J Biol Chem. 2007;282:4924–4931.CrossRefPubMedGoogle Scholar
  31. 31.
    Davidson B, Goldberg I, Reich R, et al. AlphaV and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol. 2003;90:248–257.CrossRefPubMedGoogle Scholar
  32. 32.
    Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and ovarian cancers. Histopathology. 1998;32:69–80.CrossRefPubMedGoogle Scholar
  33. 33.
    Ho EY, Choi Y, Chae SW, et al. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int. 2006;56:62–70.CrossRefGoogle Scholar
  34. 34.
    Voutilainen KA, Anttila MA, Sillanpaa SM, et al. Prognostic significance of E-cadherin–catenin complex in epithelial ovarian cancer. J Clin Pathol. 2006;59:460–467.CrossRefPubMedGoogle Scholar
  35. 35.
    Forgacs G, Foty RA, Shafrir Y, et al. Viscoelastic properties of living embryonic tissues: a quantitative study. Biophys J. 1998;74:2227–2234.CrossRefPubMedGoogle Scholar
  36. 36.
    Foty RA, Pfleger CM, Forgacs G, et al. Surface tensions of embryonic tissues predict their mutual envelopment behavior. Development. 1996;122:1611–1620.PubMedGoogle Scholar
  37. 37.
    Duguay D, Foty RA, Steinberg MS. Cadherin-mediated cell adhesion and tissue segregation: qualitative and quantitative determinants. Dev Biol. 2003;253:309–323.CrossRefPubMedGoogle Scholar
  38. 38.
    diZerega GS, Rodgers KE. The Peritoneum. New York: Springer-Verlag; 1992.Google Scholar
  39. 39.
    Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002;87:77–83.CrossRefPubMedGoogle Scholar
  40. 40.
    Rahaman J, Cohen CJ. Impact of ascites on survival in advanced ovarian cancer. Proc Am Soc Clin Oncol. 2002;21:837.Google Scholar
  41. 41.
    Ayhan A, Gultekin M, Taskiran C, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer. 2006;17:68–75.CrossRefGoogle Scholar
  42. 42.
    Gortzak-Uzan L, Ignatchenko A, Evangelou AI, et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatics analyses to identify putative biomarkers. J Proteome Res. 2008;7:339–351.CrossRefPubMedGoogle Scholar
  43. 43.
    Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1:1223–1232.PubMedGoogle Scholar
  44. 44.
    Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719–723.CrossRefPubMedGoogle Scholar
  45. 45.
    Fang X, Yu S, Bast RC, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004;279:9653–9661.CrossRefPubMedGoogle Scholar
  46. 46.
    Hagemann T, Wilson J, Burke F, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023–5032.PubMedGoogle Scholar
  47. 47.
    Reddy P, Liu L, Ren C, et al. Formation of E-cadherin mediated cell–cell adhesion activates AKT and MAPK via PI3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol Endocrinol. 2005;19:2564–2578.CrossRefPubMedGoogle Scholar
  48. 48.
    Hudson LG, Zeineldin R, Silberberg M, et al. Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res. 2009;149.Google Scholar
  49. 49.
    Lafky JM, Wilken JA, Baron AT, et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785:232–265.PubMedGoogle Scholar
  50. 50.
    Said N, Socha MJ, Olearczyk JJ, et al. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res. 2007;5:1015–1030.CrossRefPubMedGoogle Scholar
  51. 51.
    Santala M, Risteli J, Risteli L, et al. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer. Br J Cancer. 1998;77:1825–1831.PubMedGoogle Scholar
  52. 52.
    Abdel Axia MT, Abdel Aziz Wassef M, Kamel M, et al. Clinical evaluation of serum aminoterminal propeptide of type III procollagen as tumor marker in gynecologic malignancies. Tumori. 1993;79:219–223.Google Scholar
  53. 53.
    Zhu GG, Risteli J, Puistola U, et al. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res. 1993;53:5028–5032.PubMedGoogle Scholar
  54. 54.
    Mills GB, Eder A, Fang X, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Res Treat. 2002;107:259–284.Google Scholar
  55. 55.
    Do TV, Symowicz JC, Berman DM, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res. 2007;5:121–131.CrossRefPubMedGoogle Scholar
  56. 56.
    Symowicz J, Adley BP, Woo MM, et al. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 2005;65:2234–2242.CrossRefPubMedGoogle Scholar
  57. 57.
    Fishman DA, Liu, Y, Ellerbroek SM, et al. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001;61:3194–3199.PubMedGoogle Scholar
  58. 58.
    Graves LE, Ariztia EV, Navari JR, et al. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res. 2004;64:7045–7049.CrossRefPubMedGoogle Scholar
  59. 59.
    Lee Z, Swaby RF, Liang Y, et al. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006;66:2740–2748.CrossRefPubMedGoogle Scholar
  60. 60.
    Said NA, Najwer I, Socha MJ, et al. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia. 2007;9:23–35.CrossRefPubMedGoogle Scholar
  61. 61.
    Robinson-Smith TM, Isaacsohn I, Mercer CA, et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67:5708–5716.CrossRefPubMedGoogle Scholar
  62. 62.
    Hageman T, Robinson SC, Thompson RG, et al. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007;6:1993–2002.CrossRefGoogle Scholar
  63. 63.
    Kassis J, Lkominek J, Kohn EC. Tumor microenvironment: what can effusions teach us? Diagn Cytopathol. 2004;33:316–319.CrossRefGoogle Scholar
  64. 64.
    Greenaway J, Moorehead R, Shaw P, et al. Epithelial–stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol. 2008;108:385–394.CrossRefPubMedGoogle Scholar
  65. 65.
    Zietarska M, Maugard CM, Filali-Mouhim A, et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog. 2007;46:872–885.CrossRefPubMedGoogle Scholar
  66. 66.
    Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer initiating cells from primary human tumors. Cancer Res. 2008;68:4311–4320.CrossRefPubMedGoogle Scholar
  67. 67.
    Hegedus B, Marga F, Jakab K, et al. The interplay of cell–cell and cell–matrix interactions in the invasive properties of brain tumors. Biophys J. 2006;91:2708–2720.CrossRefPubMedGoogle Scholar
  68. 68.
    Battifora H, McCaughey WTE. Tumors of the serosal membranes. In: Atlas of Tumor Pathology, Third Series, Fascicle 15. Washington, DC: Armed Forces Institute of Pathology; 1994:1–117.Google Scholar
  69. 69.
    Zhang XY, Pettengell R, Nasiri N, et al. Characteristics and growth patterns of human peritoneal mesothelial cells: comparison between advanced epithelial ovarian cancer and non-ovarian cancer sources. J Soc Gynecol Investig. 1999;6:333–340.CrossRefPubMedGoogle Scholar
  70. 70.
    Wang E, Ngalame Y, Panelli MC, et al. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res. 11:113–122.Google Scholar
  71. 71.
    Cannistra SA, Kansas GS, Niloff J. et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993;53:3830–3838.PubMedGoogle Scholar
  72. 72.
    Ahmed N, Riley C, Rice G, et al. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 2005;22:391–402.CrossRefPubMedGoogle Scholar
  73. 73.
    Niedbala MJ, Crickard K, Bernacki RJ. In vitro degradation of extracellular matrix by human ovarian carcinoma cells. Clin Exp Metastasis. 1987;5:181–197.CrossRefPubMedGoogle Scholar
  74. 74.
    Sawada M, Shii J, Akedo H, et al. An experimental model for ovarian tumor invasion of cultured mesothelial cell monolayer. Lab Invest. 1994;70:333–338.PubMedGoogle Scholar
  75. 75.
    Harvey W, Amlot, P. Colalgen production by human mesothelial cells in vitro. J Pathol. 1983;139:337–347.CrossRefPubMedGoogle Scholar
  76. 76.
    Stylianou E, Jenner LA, Davies M, et al. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int. 1990;37:1563–1570.CrossRefPubMedGoogle Scholar
  77. 77.
    Ellerbroek SM, Wu YI, Overall CM, et al. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem. 2001;276:24833–24842.CrossRefPubMedGoogle Scholar
  78. 78.
    Hotary KB, Allen ED, Brooks PC, et al. Membrane type 1 matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 2003;114:33–45.CrossRefPubMedGoogle Scholar
  79. 79.
    Symowicz J, Adley BP, Gleason KJ, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 2007;67:2030–2039.CrossRefPubMedGoogle Scholar
  80. 80.
    Barbolina M, Adley, BP, Kelly, et al. Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest. 2008;88:602–614.CrossRefPubMedGoogle Scholar
  81. 81.
    Barbolina MV, Adley BP, Shea LD, et al. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer. 2008;112:1632–1641.CrossRefPubMedGoogle Scholar
  82. 82.
    BarbolinaMV, Adley BP, Kelly DL, et al. Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int J Cancer. 2009 (in press).Google Scholar
  83. 83.
    Langer S, Singer CF, Hudelist G, et al. Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters. Eur J Gynaecol Oncol. 2006;27:345–352.PubMedGoogle Scholar
  84. 84.
    Zhai Y, Hotary KB, Nan B, et al. Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res. 2005;65:6543–6550.CrossRefPubMedGoogle Scholar
  85. 85.
    Schaller G, Fuchs I, Ebert A, et al. The clinical importance of keratin 18 in breast cancer. Zentralbl Gynakol. 1999;121:126–130.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Maria V. Barbolina
    • 1
  • Natalie M. Moss
    • 2
  • Suzanne D. Westfall
    • 3
  • Yueying Liu
    • 3
  • Rebecca J. Burkhalter
    • 3
  • Francoise Marga
    • 4
  • Gabor Forgacs
    • 5
  • Laurie G. Hudson
    • 6
  • M. Sharon Stack
    • 7
  1. 1.Department of Biopharmaceutical SciencesUniversity of IllinoisChicagoUSA
  2. 2.Department of Cell & Molecular BiologyNorthwestern UniversityChicagoUSA
  3. 3.Departments of Pathology & Anatomical SciencesUniversity of Missouri School of MedicineColumbiaUSA
  4. 4.Departments of PhysicsUniversity of Missouri School of MedicineColumbiaUSA
  5. 5.Departments of Physics; Biological Sciences; Biomedical EngineeringUniversity of Missouri School of MedicineColumbiaUSA
  6. 6.Department of Pharmaceutical Sciences, College of PharmacyUniversity of New MexicoAlbuquerqueUSA
  7. 7.Department of Pathology & Anatomical Sciences1 Hospital Drive, Room M214C Medical Sciences Bldg.ColumbiaUSA

Personalised recommendations